

PSMA PET/CT

(Prostate specific membrane antigen)

PSMA PET/CT is a new type of PET/CT scan that measures prostate specific membrane antigen (PSMA). PSMA is a trans-membrane protein with intracellular and extracellular placement within the prostate cancer cell. It is substantially higher in malignant cells; PSMA is overexpressed in >80-% of men with prostate cancer.¹⁻⁶

PSMA PET/CT is approved for both initial staging of recently diagnosed prostate cancer, as well as the evaluation of possible local recurrence or metastatic disease in patients with previous treatment.

How is PSMA PET/CT used?

- For staging prostate cancer
- To evaluate possible local recurrence or metastatic disease
- As a noninvasive prognostic biomarker
- As a highly useful tool to guide personalized treatment

PSMA PET-CT in the diagnosis of localized and advanced disease

- The ProPSMA trial concluded that “PSMA PET-CT is a suitable replacement for conventional imaging, providing superior accuracy, to the combined findings of CT and bone scanning.”⁷
- PSMA demonstrated 92% detection accuracy vs 65% with conventional imaging⁷

PSMA PET-CT as a prognostic biomarker

- The absence of PSMA expression level was positively correlated with 5-year survival rates⁴
- PSMA PET-CT offers detection of a clinically relevant biomarker using a noninvasive diagnostic tool^{8,9}

PSMA PET-CT to guide treatment decisions

- PSMA PET-CT may help guide clinical management with a tailored approach and enable more therapy options¹⁰
- PSMA PET/CT after conventional imaging led to management changes in approximately 60% of patients^{10,11}

Would you like to know more?

The nuclear medicine specialists at IHS are happy to share additional information with you about PSMA PET-CT, including both current and future applications as well as patient experiences.

For more information, please email us at info@imaginghealthcare.com.

